Amy Manning-Bog - woman in black jacket with white background

Dr. Amy Manning-Boğ


Executive Management


Chief Innovation Officer



As Chief Innovation Officer, Amy is responsible for leading the identification and translation of MRIGlobal proprietary intellectual property into commercialization opportunities through licensing, royalties, and new business venture start-ups. She also leads MRIGlobal’s translational development team.

Manning-Boğ has built her career on being a scientific leader and executive in discovery research and translation with a history of achievement in strategic planning, operations, and financial goals in small and mid-sized companies. She has led from concept to development many innovative, novel therapeutics including biologics, small molecules, and gene-modifying agents across multiple domains including neuroscience, oncology, and metabolic diseases. She has a strong track record of leading and contributing effectively in multidisciplinary and team-based environments that are fast-paced, collaborative, and scientifically rigorous.  


Amy is the proud mom of two young men, both Eagle Scouts, and enjoys hiking with her sons and husband. Amy is an advocate for protecting voting rights and has served as a mentor for young women in the Cristo Rey Academy program in the San Francisco Bay Area. Amy joined MRIGlobal in 2022, following seven years with Atreca, Inc.. While there, she served in various roles, contributing to key decisions regarding platform strategy, pipeline development, and program advancement for internal studies and external-facing collaborations with large pharmaceutical companies.


BS, Biology, Missouri State University

Interdisciplinary PhD, Molecular Biology and Biochemistry, University of Missouri-Kansas City

Post-doctoral research fellow, Neuropharmacology, Wayne State University

Post-doctoral research fellow, Neurodegeneration, The Parkinson’s Institute